Switching from injectable to oral antipsychotics in schizophrenia
Part of Mental health clinical trials.
This study tests switching from a long-acting injectable antipsychotic (paliperidone palmitate) to daily oral antipsychotics in people with schizophrenia who are currently stable. The goal is to see if the switch helps maintain symptom control and improve daily functioning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with schizophrenia (based on standard criteria).
- You are currently taking an antipsychotic medication (not clozapine) and your symptoms are moderately stable.
- You have no other major mental health diagnoses, serious physical illnesses, or brain disorders.
- You have not had two or more previous antipsychotic treatments fail to work for you.
- You are not allergic to risperidone or paliperidone.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new version of an extended-release injection is as effective as the original in people with schizophrenia. The study helps ensure patients have access to a reliable treatment option.
This trial tests a medication called paliperidone for adults with schizophrenia. If you have been diagnosed for at least 3 months and haven't had success with one antipsychotic or haven't taken any yet, this study might help find a treatment that works better for you.
This study looks at long-acting (extended-release) antipsychotic medicine options in people with schizophrenia, compared with regular tablets. You may be able to join if you were already part of a related earlier study or its real-world follow-up.
This trial tests a new long-acting injection of brexpiprazole, an antipsychotic that may help control schizophrenia symptoms. The study will see how the injection is absorbed, its safety, and how well people tolerate it, potentially offering a longer-lasting treatment option.
This trial tests a monthly injection of cariprazine (a medication for mental health conditions) in people who could benefit from it. It aims to see if the shot is safe, tolerable, and effective compared to taking pills every day.
This trial tests a long-acting injectable form of cariprazine (AX251 LAI) for people with stable schizophrenia. You would receive one injection and stay at the clinic for 7 days to see how your body handles it and how well you tolerate it.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.